查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1862186

植物藥：全球市場佔有率和排名、總收入和需求預測（2025-2031 年）

Botanical Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 104 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球植物藥市場預計在 2024 年達到 369.21 億美元，預計到 2031 年將達到 490.76 億美元，在預測期（2025-2031 年）內以 4.3% 的複合年成長率成長。

植物藥是指源自天然植物或其活性成分，並經現代藥學科學、生產過程和臨床研究開發的治療產品。與合成化學藥物相比，植物藥具有天然來源、成分複雜、作用機制多標靶等特點，融合了傳統醫學理論與現代科學成果。這包括符合國際監管標準的中藥製劑和植物來源植物藥。植物藥應用廣泛，涵蓋慢性病管理、抗感染治療、心血管疾病治療、腫瘤治療及免疫調節等領域。其研發和生產嚴格遵循GMP規範和先進的品管體系，以確保產品的一致性、有效性和安全性。近年來，在消費者對天然健康解決方案日益成長的偏好以及精準醫療興起的推動下，植物藥已成為全球醫藥市場的重要組成部分，並獲得了政策支持和投資者的廣泛關注。

在監管支持和市場需求的雙重推動下，全球植物藥產業蓬勃發展。世界各地的監管機構正致力於制定草藥註冊標準和藥典規範，加速植物藥的全球化進程。日益增強的健康意識和消費者對天然療法的偏好創造了巨大的市場潛力。隨著人口老化和慢性病的盛行率上升，植物藥在心血管疾病管理、糖尿病治療以及癌症康復等方面發揮重要作用。跨國製藥公司的資本投入和積極參與推動了創新，而標準化萃取技術、活性成分分析和智慧製造技術的進步則加速了植物藥的商業化和國際市場擴張。

儘管前景光明，植物藥產業仍面臨諸多挑戰，包括複雜的臨床檢驗、漫長的監管核准流程以及品質標準不一致等。植物來源的複雜性要求企業在研發和品管方面投入巨資，尤其要滿足美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 的嚴格核准標準。智慧財產權保護依然是一大難題，仿冒品會影響品牌聲譽和市場誠信。原料成本易受環境和氣候因素影響，導致供應鏈不穩定。日益嚴格的監管和貿易壁壘迫使企業在合規、研發和市場拓展方面投入巨資，從而提高了市場進入門檻。

全球消費者對天然、永續和個人化醫療保健解決方案日益成長的偏好，正在推動植物藥市場的發展。製藥公司正迅速開發標準化的植物製劑，同時拓展機能性食品和保健產品領域。植物藥在醫院、藥局和線上銷售管道越來越受歡迎，尤其是在慢性病照護、癌症治療輔助和健康療法方面。跨境電商和全球行銷策略正在協助具有獨特文化特色的植物藥品牌走向國際市場。此外，數位健康平台、產品溯源系統和個人化醫療正在推動植物藥從傳統治療方法轉型為現代精準醫療解決方案。

植物藥的生產依賴多種藥用植物資源，生產過程包括栽培、採收、加工和初級提取。先進的栽培技術和生態友善的採收方法對於確保穩定、高品質的供應鏈至關重要。對永續農業和良好農業規範（GAP）認證農場的日益重視，正在提升草藥成分的可追溯性和品質一致性。隨著氣候變遷和保護政策限制了野生植物的收集，中國、印度和東南亞等地區興起了大規模商業化種植，形成了全球供應基地。萃取和純化技術的進步實現了成分的標準化，從而支持了高品質藥物的研發和監管合規性。全球化的採購網路和現代化的物流基礎設施使企業能夠更好地應對季節性和波動性的市場需求。

本報告旨在按地區/國家、類型和應用對全球植物藥市場進行全面分析，重點關注總銷售額、市場佔有率和主要企業的排名。

本報告以收益為準，對植物藥市場規模、估算和預測進行了呈現，以2024年為基準年，並包含了2020年至2031年的歷史數據和預測數據。報告運用定量和定性分析，幫助讀者制定業務/成長策略，評估市場競爭格局，分析自身在當前市場中的地位，並就植物藥相關業務做出明智的決策。

市場區隔

公司

  • Buchang Pharmaceuticals
  • China TCM
  • Tsumura
  • Schwabe
  • Tong Ren Tang
  • Jumpcan Pharmaceutical
  • Guangzhou Baiyunshan Pharmaceutical
  • Yunnan Baiyao
  • Tasly Holding Group
  • Bionorica Se
  • Huarun 999
  • Taiji
  • Weleda
  • Kwangdong
  • GW Pharmaceuticals

按類型分類的細分市場

  • 處方藥
  • 非處方藥

應用領域

  • 循環系統
  • 瘤
  • 呼吸系統
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Botanical Drug was estimated to be worth US$ 36921 million in 2024 and is forecast to a readjusted size of US$ 49076 million by 2031 with a CAGR of 4.3% during the forecast period 2025-2031.

Botanical drugs are therapeutic products derived from natural plants or their active ingredients, developed through modern pharmaceutical science, manufacturing processes, and clinical research. Compared with synthetic chemical drugs, botanical drugs feature natural origins, complex compositions, and multi-target mechanisms, representing a fusion of traditional medicine theories and modern scientific advancements. They include both traditional herbal preparations and innovative botanical-based drugs that meet international regulatory standards, with applications spanning chronic disease management, anti-infective therapies, cardiovascular care, oncology, and immunomodulation. Their development and production strictly follow GMP guidelines and advanced quality control systems to ensure consistency, efficacy, and safety. In recent years, driven by consumer preference for natural health solutions and the rise of precision medicine, botanical drugs have emerged as a key segment of the global pharmaceutical market, attracting strong policy support and investor interest.

The global botanical drug industry is experiencing growth fueled by both regulatory support and market demand. Regulatory agencies worldwide are refining herbal medicine registration standards and pharmacopoeia specifications, accelerating the globalization of botanical drugs. Rising health awareness and consumer preference for natural therapies create vast market potential. With aging populations and increasing prevalence of chronic diseases, botanical drugs are playing a vital role in cardiovascular health, diabetes care, oncology recovery, and more. Capital investment and active participation by multinational pharmaceutical companies are driving innovation, while advances in standardized extraction, active compound analysis, and intelligent manufacturing are accelerating commercialization and international market expansion.

Despite promising prospects, the botanical drug sector faces significant hurdles, including complex clinical validation, lengthy regulatory approval processes, and inconsistent quality standards. The inherent complexity of plant-based formulations requires substantial investment in R&D and quality control, particularly to meet stringent FDA and EMA approval criteria. Intellectual property protection remains a challenge, with counterfeit products impacting brand reputation and market order. Raw material costs are sensitive to environmental and climatic factors, leading to supply chain instability. Stricter regulations and trade barriers further compel companies to invest heavily in compliance, R&D, and market expansion, raising barriers to entry.

Global consumers' growing preference for natural, sustainable, and personalized healthcare solutions is energizing the botanical drug market. Pharmaceutical companies are rapidly developing standardized botanical formulations while extending their reach into functional foods and health management products. Botanical drugs are gaining traction in hospitals, pharmacies, and online sales channels, particularly for chronic disease care, oncology support, and wellness therapies. Cross-border e-commerce and global marketing strategies are helping culturally distinctive botanical brands expand internationally. Additionally, digital health platforms, product traceability systems, and personalized medicine are shaping the transition of botanical drugs from traditional remedies to modern precision healthcare solutions.

The backbone of botanical drug manufacturing lies in diverse medicinal plant resources, with production involving cultivation, harvesting, processing, and primary extraction. Advanced cultivation methods and ecological harvesting practices have become essential for securing a stable, high-quality supply chain. Growing emphasis on sustainable farming and GAP-certified plantations has improved traceability and consistency of herbal materials. As wild harvesting faces constraints due to climate change and conservation policies, large-scale commercial cultivation has emerged in regions such as China, India, and Southeast Asia, forming global supply hubs. Progress in extraction and purification technologies is enabling standardized raw materials, supporting high-end drug development and regulatory compliance. A globalized sourcing network and modern logistics infrastructure now allow companies to better manage seasonal fluctuations and dynamic market demands.

This report aims to provide a comprehensive presentation of the global market for Botanical Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Botanical Drug by region & country, by Type, and by Application.

The Botanical Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Botanical Drug.

Market Segmentation

By Company

  • Buchang Pharmaceuticals
  • China TCM
  • Tsumura
  • Schwabe
  • Tong Ren Tang
  • Jumpcan Pharmaceutical
  • Guangzhou Baiyunshan Pharmaceutical
  • Yunnan Baiyao
  • Tasly Holding Group
  • Bionorica Se
  • Huarun 999
  • Taiji
  • Weleda
  • Kwangdong
  • GW Pharmaceuticals

Segment by Type

  • Prescription Drug
  • OTC

Segment by Application

  • Cardiovascular
  • Tumor
  • Respiratory System
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Botanical Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Botanical Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Botanical Drug in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Botanical Drug Product Introduction
  • 1.2 Global Botanical Drug Market Size Forecast (2020-2031)
  • 1.3 Botanical Drug Market Trends & Drivers
    • 1.3.1 Botanical Drug Industry Trends
    • 1.3.2 Botanical Drug Market Drivers & Opportunity
    • 1.3.3 Botanical Drug Market Challenges
    • 1.3.4 Botanical Drug Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Botanical Drug Players Revenue Ranking (2024)
  • 2.2 Global Botanical Drug Revenue by Company (2020-2025)
  • 2.3 Key Companies Botanical Drug Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Botanical Drug Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Botanical Drug
  • 2.6 Botanical Drug Market Competitive Analysis
    • 2.6.1 Botanical Drug Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Botanical Drug Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Botanical Drug as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Prescription Drug
    • 3.1.2 OTC
  • 3.2 Global Botanical Drug Sales Value by Type
    • 3.2.1 Global Botanical Drug Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Botanical Drug Sales Value, by Type (2020-2031)
    • 3.2.3 Global Botanical Drug Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Cardiovascular
    • 4.1.2 Tumor
    • 4.1.3 Respiratory System
    • 4.1.4 Other
  • 4.2 Global Botanical Drug Sales Value by Application
    • 4.2.1 Global Botanical Drug Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Botanical Drug Sales Value, by Application (2020-2031)
    • 4.2.3 Global Botanical Drug Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Botanical Drug Sales Value by Region
    • 5.1.1 Global Botanical Drug Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Botanical Drug Sales Value by Region (2020-2025)
    • 5.1.3 Global Botanical Drug Sales Value by Region (2026-2031)
    • 5.1.4 Global Botanical Drug Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Botanical Drug Sales Value, 2020-2031
    • 5.2.2 North America Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Botanical Drug Sales Value, 2020-2031
    • 5.3.2 Europe Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Botanical Drug Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Botanical Drug Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Botanical Drug Sales Value, 2020-2031
    • 5.5.2 South America Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Botanical Drug Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Botanical Drug Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Botanical Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Botanical Drug Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Botanical Drug Sales Value, 2020-2031
    • 6.3.2 United States Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Botanical Drug Sales Value, 2020-2031
    • 6.4.2 Europe Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Botanical Drug Sales Value, 2020-2031
    • 6.5.2 China Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Botanical Drug Sales Value, 2020-2031
    • 6.6.2 Japan Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Botanical Drug Sales Value, 2020-2031
    • 6.7.2 South Korea Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Botanical Drug Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Botanical Drug Sales Value, 2020-2031
    • 6.9.2 India Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Botanical Drug Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Buchang Pharmaceuticals
    • 7.1.1 Buchang Pharmaceuticals Profile
    • 7.1.2 Buchang Pharmaceuticals Main Business
    • 7.1.3 Buchang Pharmaceuticals Botanical Drug Products, Services and Solutions
    • 7.1.4 Buchang Pharmaceuticals Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Buchang Pharmaceuticals Recent Developments
  • 7.2 China TCM
    • 7.2.1 China TCM Profile
    • 7.2.2 China TCM Main Business
    • 7.2.3 China TCM Botanical Drug Products, Services and Solutions
    • 7.2.4 China TCM Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.2.5 China TCM Recent Developments
  • 7.3 Tsumura
    • 7.3.1 Tsumura Profile
    • 7.3.2 Tsumura Main Business
    • 7.3.3 Tsumura Botanical Drug Products, Services and Solutions
    • 7.3.4 Tsumura Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Tsumura Recent Developments
  • 7.4 Schwabe
    • 7.4.1 Schwabe Profile
    • 7.4.2 Schwabe Main Business
    • 7.4.3 Schwabe Botanical Drug Products, Services and Solutions
    • 7.4.4 Schwabe Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Schwabe Recent Developments
  • 7.5 Tong Ren Tang
    • 7.5.1 Tong Ren Tang Profile
    • 7.5.2 Tong Ren Tang Main Business
    • 7.5.3 Tong Ren Tang Botanical Drug Products, Services and Solutions
    • 7.5.4 Tong Ren Tang Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Tong Ren Tang Recent Developments
  • 7.6 Jumpcan Pharmaceutical
    • 7.6.1 Jumpcan Pharmaceutical Profile
    • 7.6.2 Jumpcan Pharmaceutical Main Business
    • 7.6.3 Jumpcan Pharmaceutical Botanical Drug Products, Services and Solutions
    • 7.6.4 Jumpcan Pharmaceutical Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Jumpcan Pharmaceutical Recent Developments
  • 7.7 Guangzhou Baiyunshan Pharmaceutical
    • 7.7.1 Guangzhou Baiyunshan Pharmaceutical Profile
    • 7.7.2 Guangzhou Baiyunshan Pharmaceutical Main Business
    • 7.7.3 Guangzhou Baiyunshan Pharmaceutical Botanical Drug Products, Services and Solutions
    • 7.7.4 Guangzhou Baiyunshan Pharmaceutical Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Guangzhou Baiyunshan Pharmaceutical Recent Developments
  • 7.8 Yunnan Baiyao
    • 7.8.1 Yunnan Baiyao Profile
    • 7.8.2 Yunnan Baiyao Main Business
    • 7.8.3 Yunnan Baiyao Botanical Drug Products, Services and Solutions
    • 7.8.4 Yunnan Baiyao Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Yunnan Baiyao Recent Developments
  • 7.9 Tasly Holding Group
    • 7.9.1 Tasly Holding Group Profile
    • 7.9.2 Tasly Holding Group Main Business
    • 7.9.3 Tasly Holding Group Botanical Drug Products, Services and Solutions
    • 7.9.4 Tasly Holding Group Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Tasly Holding Group Recent Developments
  • 7.10 Bionorica Se
    • 7.10.1 Bionorica Se Profile
    • 7.10.2 Bionorica Se Main Business
    • 7.10.3 Bionorica Se Botanical Drug Products, Services and Solutions
    • 7.10.4 Bionorica Se Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Bionorica Se Recent Developments
  • 7.11 Huarun 999
    • 7.11.1 Huarun 999 Profile
    • 7.11.2 Huarun 999 Main Business
    • 7.11.3 Huarun 999 Botanical Drug Products, Services and Solutions
    • 7.11.4 Huarun 999 Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Huarun 999 Recent Developments
  • 7.12 Taiji
    • 7.12.1 Taiji Profile
    • 7.12.2 Taiji Main Business
    • 7.12.3 Taiji Botanical Drug Products, Services and Solutions
    • 7.12.4 Taiji Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Taiji Recent Developments
  • 7.13 Weleda
    • 7.13.1 Weleda Profile
    • 7.13.2 Weleda Main Business
    • 7.13.3 Weleda Botanical Drug Products, Services and Solutions
    • 7.13.4 Weleda Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Weleda Recent Developments
  • 7.14 Kwangdong
    • 7.14.1 Kwangdong Profile
    • 7.14.2 Kwangdong Main Business
    • 7.14.3 Kwangdong Botanical Drug Products, Services and Solutions
    • 7.14.4 Kwangdong Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Kwangdong Recent Developments
  • 7.15 GW Pharmaceuticals
    • 7.15.1 GW Pharmaceuticals Profile
    • 7.15.2 GW Pharmaceuticals Main Business
    • 7.15.3 GW Pharmaceuticals Botanical Drug Products, Services and Solutions
    • 7.15.4 GW Pharmaceuticals Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.15.5 GW Pharmaceuticals Recent Developments

8 Industry Chain Analysis

  • 8.1 Botanical Drug Industrial Chain
  • 8.2 Botanical Drug Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Botanical Drug Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Botanical Drug Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Botanical Drug Market Trends
  • Table 2. Botanical Drug Market Drivers & Opportunity
  • Table 3. Botanical Drug Market Challenges
  • Table 4. Botanical Drug Market Restraints
  • Table 5. Global Botanical Drug Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Botanical Drug Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Botanical Drug Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Botanical Drug Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Botanical Drug
  • Table 10. Global Botanical Drug Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Botanical Drug as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Botanical Drug Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Botanical Drug Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Botanical Drug Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Botanical Drug Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Botanical Drug Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Botanical Drug Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Botanical Drug Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Botanical Drug Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Botanical Drug Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Botanical Drug Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Botanical Drug Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Botanical Drug Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Botanical Drug Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Botanical Drug Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Botanical Drug Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Botanical Drug Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Botanical Drug Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Botanical Drug Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Buchang Pharmaceuticals Basic Information List
  • Table 32. Buchang Pharmaceuticals Description and Business Overview
  • Table 33. Buchang Pharmaceuticals Botanical Drug Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Botanical Drug Business of Buchang Pharmaceuticals (2020-2025)
  • Table 35. Buchang Pharmaceuticals Recent Developments
  • Table 36. China TCM Basic Information List
  • Table 37. China TCM Description and Business Overview
  • Table 38. China TCM Botanical Drug Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Botanical Drug Business of China TCM (2020-2025)
  • Table 40. China TCM Recent Developments
  • Table 41. Tsumura Basic Information List
  • Table 42. Tsumura Description and Business Overview
  • Table 43. Tsumura Botanical Drug Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Botanical Drug Business of Tsumura (2020-2025)
  • Table 45. Tsumura Recent Developments
  • Table 46. Schwabe Basic Information List
  • Table 47. Schwabe Description and Business Overview
  • Table 48. Schwabe Botanical Drug Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Botanical Drug Business of Schwabe (2020-2025)
  • Table 50. Schwabe Recent Developments
  • Table 51. Tong Ren Tang Basic Information List
  • Table 52. Tong Ren Tang Description and Business Overview
  • Table 53. Tong Ren Tang Botanical Drug Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Botanical Drug Business of Tong Ren Tang (2020-2025)
  • Table 55. Tong Ren Tang Recent Developments
  • Table 56. Jumpcan Pharmaceutical Basic Information List
  • Table 57. Jumpcan Pharmaceutical Description and Business Overview
  • Table 58. Jumpcan Pharmaceutical Botanical Drug Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Botanical Drug Business of Jumpcan Pharmaceutical (2020-2025)
  • Table 60. Jumpcan Pharmaceutical Recent Developments
  • Table 61. Guangzhou Baiyunshan Pharmaceutical Basic Information List
  • Table 62. Guangzhou Baiyunshan Pharmaceutical Description and Business Overview
  • Table 63. Guangzhou Baiyunshan Pharmaceutical Botanical Drug Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Botanical Drug Business of Guangzhou Baiyunshan Pharmaceutical (2020-2025)
  • Table 65. Guangzhou Baiyunshan Pharmaceutical Recent Developments
  • Table 66. Yunnan Baiyao Basic Information List
  • Table 67. Yunnan Baiyao Description and Business Overview
  • Table 68. Yunnan Baiyao Botanical Drug Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Botanical Drug Business of Yunnan Baiyao (2020-2025)
  • Table 70. Yunnan Baiyao Recent Developments
  • Table 71. Tasly Holding Group Basic Information List
  • Table 72. Tasly Holding Group Description and Business Overview
  • Table 73. Tasly Holding Group Botanical Drug Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Botanical Drug Business of Tasly Holding Group (2020-2025)
  • Table 75. Tasly Holding Group Recent Developments
  • Table 76. Bionorica Se Basic Information List
  • Table 77. Bionorica Se Description and Business Overview
  • Table 78. Bionorica Se Botanical Drug Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Botanical Drug Business of Bionorica Se (2020-2025)
  • Table 80. Bionorica Se Recent Developments
  • Table 81. Huarun 999 Basic Information List
  • Table 82. Huarun 999 Description and Business Overview
  • Table 83. Huarun 999 Botanical Drug Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Botanical Drug Business of Huarun 999 (2020-2025)
  • Table 85. Huarun 999 Recent Developments
  • Table 86. Taiji Basic Information List
  • Table 87. Taiji Description and Business Overview
  • Table 88. Taiji Botanical Drug Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Botanical Drug Business of Taiji (2020-2025)
  • Table 90. Taiji Recent Developments
  • Table 91. Weleda Basic Information List
  • Table 92. Weleda Description and Business Overview
  • Table 93. Weleda Botanical Drug Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Botanical Drug Business of Weleda (2020-2025)
  • Table 95. Weleda Recent Developments
  • Table 96. Kwangdong Basic Information List
  • Table 97. Kwangdong Description and Business Overview
  • Table 98. Kwangdong Botanical Drug Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Botanical Drug Business of Kwangdong (2020-2025)
  • Table 100. Kwangdong Recent Developments
  • Table 101. GW Pharmaceuticals Basic Information List
  • Table 102. GW Pharmaceuticals Description and Business Overview
  • Table 103. GW Pharmaceuticals Botanical Drug Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Botanical Drug Business of GW Pharmaceuticals (2020-2025)
  • Table 105. GW Pharmaceuticals Recent Developments
  • Table 106. Key Raw Materials Lists
  • Table 107. Raw Materials Key Suppliers Lists
  • Table 108. Botanical Drug Downstream Customers
  • Table 109. Botanical Drug Distributors List
  • Table 110. Research Programs/Design for This Report
  • Table 111. Key Data Information from Secondary Sources
  • Table 112. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Botanical Drug Product Picture
  • Figure 2. Global Botanical Drug Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Botanical Drug Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Botanical Drug Report Years Considered
  • Figure 5. Global Botanical Drug Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Botanical Drug Revenue in 2024
  • Figure 7. Botanical Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Prescription Drug Picture
  • Figure 9. OTC Picture
  • Figure 10. Global Botanical Drug Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Botanical Drug Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Cardiovascular
  • Figure 13. Product Picture of Tumor
  • Figure 14. Product Picture of Respiratory System
  • Figure 15. Product Picture of Other
  • Figure 16. Global Botanical Drug Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global Botanical Drug Sales Value Market Share by Application, 2024 & 2031
  • Figure 18. North America Botanical Drug Sales Value (2020-2031) & (US$ Million)
  • Figure 19. North America Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Europe Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Europe Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Asia Pacific Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Asia Pacific Botanical Drug Sales Value by Region (%), 2024 VS 2031
  • Figure 24. South America Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. South America Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Middle East & Africa Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Middle East & Africa Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Key Countries/Regions Botanical Drug Sales Value (%), (2020-2031)
  • Figure 29. United States Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. United States Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 31. United States Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 32. Europe Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 34. Europe Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 35. China Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. China Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 37. China Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 38. Japan Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Japan Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 40. Japan Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 41. South Korea Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. South Korea Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 43. South Korea Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 44. Southeast Asia Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. Southeast Asia Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 46. Southeast Asia Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 47. India Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. India Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 49. India Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 50. Botanical Drug Industrial Chain
  • Figure 51. Botanical Drug Manufacturing Cost Structure
  • Figure 52. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 53. Bottom-up and Top-down Approaches for This Report
  • Figure 54. Data Triangulation
  • Figure 55. Key Executives Interviewed